Novo Nordisk: New data with dual agonist set a potential new SoC
Novo Nordisk: (NEUTRAL, Fair Value DKK330 (+17%))New data with dual agonist set a potential new SoC
Yesterday Lilly presented at the EASD congress in Berlin and simultaneously in The Lancet the phaseIIb results for its new investigational dual GIP and GLP-1 receptor agonist LY3298176. They are actually very impressive in terms of efficacy and set a potential new standard of care in how to treat type II diabetes since the reduction in HbA1C but also the impact on weight were both unprecedented with a single product which is injected once weekly. Lilly now plans to start ambitious phase III programme (which includes a direct head-to-head trial vs Ozempic) with a reasonable filing time in 2021/2022. This will be a very serious competitor to Novo’s injectable GLP-1 business and although oral semaglutide will open a new opportunity, it is very likely to be a tough product to circumvent in the years to come. We will fully assess the potential impact on the numbers and FV in the coming days.
Novo-Nordisk is a global healthcare company engaged in the innovation of diabetes care. Co. also provides haemophilia care, growth hormone therapy and hormone replacement therapy. The Diabetes care business segment includes research, development, manufacturing and marketing of products within the areas of insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD) and obesity. The Biopharmaceuticals business segment includes research, development, manufacturing and marketing of products within the areas of haemophilia, growth hormone therapy, hormone replacement therapy, inflammation therapy and other therapy areas.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.